18 completed, 2 unknown, 1 not yet recruiting, 1 recruiting. 8 Phase 3, 6 Not applicable, 4 Phase 1, 2 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 8 |
| Not applicable | 6 | Completed 4, Unknown 2 |
| Phase 1 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 2 |
Follow Neurodermatitis: new trials by email Literature Review of Neurodermatitis trials Research Report on Neurodermatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief 10% High-Concentration 35 kDa Hyaluronan (HA35) Topical Anti-Pruritic Gel - Skin Pruritus, Itch | Not applicable | Completed | Nakhia Impex LLC | 30 | 2026-06-20 | 2026-09-22 |
| A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants. PG-033 tablets, PG-033 placebo comparator - Lichen Simplex Chronicus | Phase 1 | Not yet recruiting | Prime Gene Therapeutics Co., Ltd. | 30 | 2026-06-04 | 2026-06-01 |
| A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults PG-033, PG-033 placebo comparator - Lichen Simplex Chronicus | Phase 1 | Recruiting | Prime Gene Therapeutics Co., Ltd. | 52 | 2025-05-23 | 2026-06-02 |
| Effect of Extracorporeal Shockwave Therapy on Pruritus in Neurodermatitis Patients Shockwave therapy, Emollients & corticosteroids - Neurodermatitis | Not applicable | Completed | Cairo University | 34 | 2024-12-15 | 2026-03-09 |
| A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1) Dupilumab, Placebo - Lichen Simplex Chronicus | Phase 3 | Completed | Sanofi | 142 | 2024-11-28 | 2026-09-11 |
| A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2) Dupilumab, Placebo - Lichen Simplex Chronicus | Phase 3 | Completed | Sanofi | 138 | 2024-11-25 | 2026-09-11 |
| Fractional Carbon Dioxide Laser: A Novel Therapeutic Option for Lichen Simplex Chronicus Betamethasone Valerate 0.1% Cream, SmartXide® fractional carbon dioxide laser, Vaseline Topical Product - Lichen Simplex Chronicus | Not applicable | Unknown | Cairo University | 60 | 2024-03-01 | 2024-02-20 |
| The Novel Electrolyzed Water Spray Treatment Mild Senile Groin Eczema, Neurodermatitis and Psoriasis The novel electrolyzed water spray - Groin Infection, Neurodermatitis | Not applicable | Completed | Dove Medical Press Ltd | 21 | 2023-01-29 | 2024-04-25 |
| A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis si-544, Placebo - Atopic Dermatitis | Phase 1 | Completed | selectION Therapeutics GmbH | 36 | 2022-08-30 | 2023-11-13 |
| KM-001 Cream for Treatment of Pruritus in Adult Patients With Lichen Simplex Chronicus (LSC) IMP Application KM-001, Chemistry, Hematology - Lichen Simplex Chronicus | Phase 1 | Completed | Orvida Pharma (formerly Kamari Pharma) | 55 | 2022-05-24 | 2024-04-02 |
| Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Nemolizumab 30 mg, Placebo - Prurigo Nodularis | Phase 3 | Completed | Galderma R&D | 286 | 2020-09-11 | 2024-07-10 |
| A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Nemolizumab, Placebo - Prurigo Nodularis | Phase 3 | Completed | Galderma R&D | 274 | 2020-08-11 | 2024-07-10 |
| Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2) Dupilumab SAR231893, Placebo, Moisturizers - Neurodermatitis | Phase 3 | Completed | Sanofi | 160 | 2020-01-16 | 2025-09-17 |
| Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME) Dupilumab SAR231893, Placebo, Moisturizers - Neurodermatitis | Phase 3 | Completed | Sanofi | 151 | 2019-12-12 | 2025-09-17 |
| A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases KPL-716, Placebo - Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus | Phase 2 | Completed | Genentech, Inc. | 58 | 2019-05-29 | 2025-03-18 |
| Pain Outcomes Following Intralesional Corticosteroid Injections Corticosteroid with lidocaine, Corticosteroid with normal saline - Keloid, Alopecia Areata | Phase 4 | Completed | Vanderbilt University Medical Center | 31 | 2018-10-01 | 2021-03-11 |
| Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis Secukinumab 300 mg, Placebo - Dermatitis, Atopic, Eczema, Atopic | Phase 2 | Completed | GWT-TUD GmbH | 22 | 2018-09-18 | 2021-05-03 |
| Dapsone Prurigo Study Dapsone gel - verum - Lichen Simples Chronicus and Prurigo | Not applicable | Unknown | Cook County Health | 20 | 2013-09-01 | 2013-06-05 |
| Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder Selegiline, Placebo (for Selegiline) - Borderline Personality Disorder | Phase 3 | Completed | Mood and Anxiety Research, Inc | 30 | 2012-10-01 | 2015-10-08 |
| Diagnostic Accuracy of "Three Rings Vulvoscopy" for Detection of Vulvar Dermatosis "Three Rings Vulvoscopy" (TRIV), Histopathology - Lichen Sclerosus, Lichen Planus | Not applicable | Completed | Ginekološka Poliklinika Dr. Vesna Harni | 328 | 2011-12-01 | 2019-10-30 |
Showing 20 of 22. Sign in to see all of them.
Pruritus (7) · Dermatitis, Atopic (3) · Lichen Planus (3) · Prurigo (3) · Depression (2) · Skin Diseases (2) · Acne Vulgaris (1) · Alopecia Areata (1) · Anxiety Disorders (1) · Borderline Personality Disorder (1) · Chronic Urticaria (1) · Cicatrix, Hypertrophic (1) · Dermoid Cyst (1) · Eczema (1)
Dermatitis (22) · Skin Diseases, Eczematous (22) · Skin and Connective Tissue Diseases (21) · Skin Diseases (20) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (8) · Skin Manifestations (7) · Hypersensitivity (5) · Hypersensitivity, Immediate (5) · Immune System Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Skin Diseases, Papulosquamous (4) · Lichenoid Eruptions (3) · Pathologic Processes (3)
dupilumab (4) · Adrenal Cortex Hormones (3) · Calcineurin Inhibitors (2) · nemolizumab (2) · Betamethasone Valerate (1) · Electrocardiography (1) · Emollients (1) · Extracorporeal Shockwave Therapy (1) · Hematologic Tests (1) · Lidocaine (1) · Pregnancy Tests (1) · Restraint, Physical (1) · Saline Solution (1) · Selegiline (1) · Urinalysis (1)
Sanofi (4) · Cairo University (2) · Galderma R&D (2) · Prime Gene Therapeutics Co., Ltd. (2) · Cook County Health (1) · Dove Medical Press Ltd (1) · GWT-TUD GmbH (1) · Genentech, Inc. (1) · Ginekološka Poliklinika Dr. Vesna Harni (1) · Max Zeller Soehne AG (1) · Mood and Anxiety Research, Inc (1) · Nakhia Impex LLC (1) · Orvida Pharma (formerly Kamari Pharma) (1) · University Medicine Greifswald (1) · Vanderbilt University Medical Center (1)
United States (10) · China (7) · Germany (7) · Canada (5) · Hungary (4) · Italy (4) · South Korea (4) · Spain (4) · United Kingdom (4) · Argentina (3) · Chile (3) · France (3) · Mexico (3) · Taiwan (3) · Belgium (2)
Andrea Ladwig (1) · Andreas Klostermann, Dr. (1) · Brian Drolet, MD (1) · Doaa Atef Aly, PhD (1) · Joerg Albrecht, MD (1) · Noha Zakaria Tawfik, PhD (1) · Paul J Markovitz, MD, PhD (1) · Peter Grendelmeier, MD (1) · Stefan Beissert, Prof. Dr. (1) · Vesna Harni, MD (1)
PMID 37142763, PMID 37888917, PMID 38865146, PMID 40266487, PMID 41219577, PMID 41922877, PMID 42120670, PMID 24435467, PMID 33760691, PMID 36375174, PMID 39602139, PMID 40767880, PMID 41272364
2019 (4), 2016 (1)